Development of Human Leukocyte Antigen (HLA) Antibodies Against Vascular Homograft Donor in Pediatric Heart Transplant Recipients

Background: The appearance of human leukocyte antigen (HLA) antibodies after solid organ transplantation predisposes recipients to graft dysfunction. In theory, vascular homografts, which are widely used in children with congenital heart defects, may cause allo sensitization.

Material/Methods: In this single-center retrospective study, the presence of pre-existing HLA antibodies in pediatric heart transplant (HTx) recipients with a vascular homograft was evaluated in a cohort of 12 patients. HLA antibodies were screened before and after HTx and positive screening results were confirmed and identified using the Luminex® single antigen bead method. Endomyocardial biopsies (EMB) and coronary angiography studies were re-evaluated to assess the prevalence of acute rejections and coronary artery change in these patients.

Results: At the time of HTx, 8 patients (67%) had HLA antibodies detected by the Luminex assay, none of which were heart donor specific (DSA). All patients had negative leukocyte crossmatch. One patient developed DSAs against homograft donor prior to HTx. After the HTx, 5 patients (42%) developed DSAs against the heart donor and 4 patients (40%) against the homograft donor. In 2 patients (17%), the antibodies were against both heart and homograft donors. The rejection rate or prevalence of coronary artery vasculopathy did not differ significantly between the homograft cohort and our historical controls.

Conclusions: Our results suggest that the prevalence of DSAs against homograft donor prior to HTx is relatively rare. However, almost half of the patients developed DSAs against homograft post-HTx. The clinical importance of these antibodies warrants further studies.

MeSH Keywords: Antibody Formation • Cadaver • Child • Heart Transplantation • HLA Antigens • Vascular Grafting

Full-text PDF: https://www.annalsoftransplantation.com/abstract/index/idArt/917232
Circulating donor-specific HLA antibodies (DSA) have been associated with increased risk for allograft vasculopathy and impaired graft survival in heart transplant (HTx) recipients [1–3]. The risk for developing DSAs is increased in patients with previous heart operations [4,5] and it has been suggested that pediatric recipients with congenital heart disease (CHD) have worse outcome than patients with cardiomyopathy [6,7]. Recent database analyses have established the presence of positive (>10%) panel reactive antibodies (PRA) before transplantation as a significant risk factor for 1-year mortality among pediatric HTx population [8].

The significance of HLA antibodies induced by vascular allografts and valve implants has remained unclear [9–12]. In patients with chronic kidney disease, vein allografts from deceased donors used for hemodialysis access have been suggested to lead to HLA sensitization [13], which may further cause humoral transplant rejection and graft dysfunction [14]. Vascular allografts have been used for decades among pediatric patients with congenital heart defects and it has been previously shown, that approximately 40% to 60% of these children develop HLA antibodies after allograft implantation [15–17]. Many of these patients with pre-existing HLA sensitization may require HTx during childhood or as adults. In the present study, we aimed to evaluate the presence of HLA antibodies against vascular homograft donor and heart transplant donor before and after HTx in a cohort of pediatric HTx patients with a vascular homograft from deceased donors. The long-term survival, number of acute rejections, and coronary arterial changes were evaluated retrospectively and compared to historical controls. We hypothesized that vascular homografts from deceased donors increases the risk for allosensitization before HTx which may further lead to increased number of rejections after HTx.

**Material and Methods**

**Patients and patient selection**

This is a single-center retrospective study of pediatric HTx recipients with a history of receiving vascular homografts from deceased donor at the Children’s Hospital, Helsinki University Hospital (ethical approval no. HUS26/2018). Since 2000, HLA antibodies have been monitored systematically and the data were collected from all study subjects or their parents.

The Research Ethics Committee of Helsinki University Hospital approved the study; an informed written consent was obtained from all study subjects or their parents.

Vascular allografts were preserved in dimethyl sulfoxide (DMSO) cryopreservant (CryoSure-DMSO, WAK-Chemie) and stored in liquid nitrogen for a maximum of 5 years. Before use, the allografts were thawed according to the standard procedure. All vascular allografts were selected based on ABO blood grouping. The vast majority of the homografts consisted of pulmonary artery grafts; in 2 patients, aortic graft was used. No immunosuppressive medication was used during or after the operation.

The immunosuppressive protocol for all HTx patients consisted of anti-thymoglobulin induction therapy and triple medication including calcineurin inhibitor, azathioprine, and methylprednisolone (MP). None of the patients were put on immunosuppressive medication after receiving of a vascular allograft from a deceased donor.

The HLA antibody status, number of biopsy proven rejections, and coronary angiography findings were analyzed retrospectively from the data collected at routine follow-up visits at our center. The follow-up consists of anti-HLA antibody tests and endomyocardial biopsies (EMB) at 1, 3, 6, 9, 12, 18, and 24 months after HTx, and annually thereafter. Coronary angiography is performed annually in patients older than 4 to 5 years of age. The patients are transferred to adult care at the age of 18 to 22 years.

One Lambda Labscreen® mixed with Luminex® was used for HLA antibody screening and PRA calculation with the use of HLA Fusion software (One Lambda Inc., Canoga Park, CA, USA). In case of a positive screening result, the presence of HLA antibodies was confirmed and identified using the Luminex® single antigen bead method. A normalized MFI cutoff point of 1000 was used for positivity in single antigen analyses. Antibodies against HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP were analyzed. These results were compared to the HLA data of both vascular allograft donors and heart donors collected from the registry of the Finnish Red Cross Blood Service.

Endomyocardial biopsies (EMB) were classified according to the ISHLT criteria [18]. Grade 1R finding was defined as immuneacti-vation. Coronary angiograms were re-evaluated by an experienced pediatric cardiologist (JP). The angiography findings were classified according to the ISHLT guidelines into CAV grades 0–3 [19].

The Risk for developing DSAs is increased in patients with pre-existing HLA sensitization may require HTx prior to HTx and in 12 cases (71%), vascular allografts from 18 deceased donors were used.

The risk for developing DSAs is increased in patients with pre-existing HLA sensitization may require HTx prior to HTx and in 12 cases (71%), vascular allografts from 18 deceased donors were used.
Table 1. Patients’ demographics and characteristics. The table presents data from patients of the present study, from patients with congenital heart defect transplanted at our institution, and from all pediatric heart transplant patients at our unit. The data have been partly presented by Raissadati et al. [20].

|                                | Present study (n=12) | Historical CHD (n=29) | Historical all (n=68) | p-Value* |
|--------------------------------|----------------------|-----------------------|-----------------------|----------|
| Female/Male, %                 | 50/50                | 42/58                 | 53/47                 | 0.873    |
| Operations before HTx, n       | 3.4±1.2              | 3.0±1.4               | 1.4±1.5               | 1.00     |
| Age at homograft insertion, years | 4.0±6.3              | NA                    | NA                    |          |
| VAD, n (%)                     | 0                    | 0                     | 6 (9)                 | 1.00     |
| Waiting time, days             | 125±210              | 168±223               | 150±201               | 0.353    |
| Age at HTx, years              | 10.8±5.8             | NA                    | 8.5±5.4               | 0.320    |
| Follow-up time after HTx, years | 5.6±4.7              | 13.2±8.0              | 12.7±7.5              | 0.009    |
| Retransplantations, n (%)      | 2 (17)               | 3 (10)                | 5 (7)                 | 0.620    |
| HLA A/B match, n (%)           | n=14                 | 2 (14)                | 3 (10)                | 9 (12)   | 0.620    |
| 0/4                            |                      | 10 (71)               | 12 (42)               | 31 (46)  | 0.165    |
| 1/4                            |                      | 2 (14)                | 7 (24)                | 16 (24)  | 0.702    |
| 3/4                            |                      | 0 (0)                 | 0 (0)                 | 4 (6)    |          |
| 4/4                            |                      | 0 (0)                 | 0 (0)                 | 0 (0)    |          |
| HLA DR match, n (%)            |                      | 6 (43)                | 8 (28)                | 27 (40)  | 0.278    |
| 0/2                            |                      | 6 (43)                | 10 (34)               | 25 (37)  | 0.485    |
| 2/2                            |                      | 2 (14)                | 4 (14)                | 8 (12)   | 1.00     |
| Mortality, n (%)               |                      | 2 (17)                | 12 (41)               | 29 (43)  | 0.165    |
| Acute cellular rejections      |                      |                       |                       |          |
| Patients, n (%)                | 7 (67)               | NA                    | NA                    |          |
| Episodes, n                    | 18                   | NA                    | NA                    |          |
| CAV at the time of the study   | n=12                 | n=22                  | n=60                  |          |
| CAV score 0, n (%)             | 4 (33)               | 12 (55)               | 38 (63)               | 0.410    |
| CAV score 1, n (%)             | 2 (17)               | 2 (9)                 | 4 (7)                 | 0.602    |
| CAV score 2, n (%)             | 3 (25)               | 2 (9)                 | 9 (15)                | 0.391    |
| CAV score 3, n (%)             | 0 (0)                | 4 (18)                | 4 (7)                 | 0.273    |
| NA                             | 3 (25)               | 2 (9)                 | 5 (8)                 |          |

CHD – congenital heart defect; HTx – heart transplant; CAV – coronary artery vasculopathy; CIT – cold ischemia time; VAD – ventricular assist device; NA – not available. Values are presented as mean ± standard deviation. * Comparison between present cohort and historical CHD patients.

**Statistical analysis**

Numerical data are presented as medians with ranges. The Mann-Whitney U test was used to compare patient groups with or without history of receiving homograft. Findings were considered statistically significant when the probability of a chance finding was less than 5% (P<0.05). SPSS version 22.0 software was used for statistical analysis.
Patient demographics

Table 1 summarizes patient characteristics of the present study in respect to all pediatric HTx patients and patients transplanted due to CHD at our institution between 1991 and 2012 [20]. In the current patient cohort, a mean of 3.4 open heart surgeries had been performed prior to HTx. In 10 patients, vascular allografts from deceased donors were inserted a median of 1.37 (0.6–16.2) years prior to HTx. In 1 patient (Patient 11), a vascular homograft was inserted at HTx, and in another patient (Patient 6), 29 days after the HTx because of invasive Candida albicans infection of the aorta (Table 2). Vascular homografts from 18 different donors were used and HLA data were available from 16 donors (89%). Two patients had retransplantation and HLA type was available from all 14 heart donors. HLA antibodies were followed up according to our standard protocol and these data were available from all 12 patients. In 9 HTx patients, both heart and homograft donors had the same HLA type in a total of 16 alleles (class I, n=10 and class II, n=6).

Results

HLA sensitization before HTx

Eight patients (67%) had HLA antibodies (PRA >10%) before HTx (Table 2). None of the pre-existing HLA antibodies were against heart donor, while 1 patient had DSA (DR1, MFI 2453) against the homograft donor. These homograft donor DSAs were detected for the first time 13.6 years after insertion of the homograft.

HLA sensitization after HTx

After HTx, a total of 7 patients (58%) developed anti-HLA antibodies. The median time from HTx to the first detection of DSAs was 69 (13–2865) days. In 5 patients (42%), the antibodies were de novo DSAs against heart donors and in 4 patients (40%), they were de novo DSAs against homograft donors. In 2 cases (Patient 4 and Patient 9), the post-HTx de novo DSAs were against both the heart and the homograft donor (Table 3). Patient 4 experienced biopsy-proven antibody-mediated rejection 2 weeks after the first HTx and developed severe coronary artery vasculopathy (CAV) later on. She was retransplanted 9 years after the first HTx. After the second HTx, she developed de novo DQ7 DSA against the heart and homograft donor (Table 3). In Patient 9, no coronary angiography or endomyocardial biopsy was performed because of her
young age. She developed 3 different DSA with MFI >4000 units within 36 days after the HTx.

Rejection rate and angiography findings

Eight patients (67%) had a total of 18 episodes of immun activations or acute rejections (AR). Three ARs (17%) were diagnosed within 3 months of HTx and 1 episode was proven to be antibody-mediated rejection (AMR). The number of rejection episodes per patient did not differ between patients with homograft (1.4) and all HTx patients (1.5). Five patients (42%) had abnormal coronary angiography findings (CAV1-2), while 36% of the historical CHD patients and 29% of all HTx patients had at least CAV1 in their angiograms (Table 3). Out of 5 patients with >CAV1, one patient had de novo DSA against both the heart and the homograft donor.

Two patients (17%) died: 1 patient died at 3.3 years after HTx from acute arrhythmia and another patient died at 2.5 months after retransplantation from posttransplant lymphoproliferative disease and sepsis.

**Discussion**

Patients with congenital heart defects are known to be at increased risk for developing HLA antibodies prior to heart transplantation [4]. Theoretically, the risk for sensitization is even higher in patients with vascular homograft from deceased donor and it has been shown that HLA sensitization may last several years after the allograft implantation [15,17]. If the homograft and heart donor share even partly the same HLA genotype, it may increase the risk for antibody-mediated rejection and graft dysfunction after HTx. In the present study, we show that DMSO-preserved homografts from deceased donors do not pose a significant risk for sensitization in pediatric HTx population. The vast majority of patients in our cohort had PRA >10% prior to HTx; with only 1 patient having HLA antibodies against the homograft donor and none against the heart donor. None of our patients had positive crossmatch in the cytotoxic assay at the time of transplantation. Five patients developed de novo DSAs post-HTx and in 2 of these patients, the DSAs were against both the homograft and the heart donor. We could not rule out a causative role of the pre-existing HLA

| Patient | Class I DSA (MFI) | Class II DSA (MFI) | AR, n | CAV gradus |
|---------|------------------|--------------------|-------|------------|
|         | Heart            | Homograft          | Heart | Homograft  |         |
| 1       | No DSA           | NA                 | No DSA| NA         | 3       |
| 2       | No DSA           | NA                 | No DSA| NA         | 2       |
| 3       | No DSA           | No DSA             | DQ2 (2734)| No DSA | 1       |
| 4       | No DSA           | No DSA             | DQ6 (5155), DQ5 (3780)| DQ6 (2662) | 4       |
| 5       | No DSA           | No DSA             | A3 (4767), B7 (4550)| DR4 (2233) |         |
| 6       | No DSA           | No DSA             | No DSA| No DSA     | 0       |
| 7       | No DSA           | B39 (2073)         | No DSA| DR1 (2046) | 2       |
| 8       | No DSA           | No DSA             | No DSA| NA         | NA      |
| 9       | A2 (4356)        | A2 (4356)          | DR4 (4428)| DR4 (4428) | NA      |
| 10      | A1 (3017), B8 (1183)| DQ7 (1976)      | No DSA| NA         | NA      |
| 11      | No DSA           | No DSA             | No DSA| No DSA     | 0       |
| 12      | A3 (1297), B51 (1154)| No DSA           | DR1 (3186), DR3 (5733), DQ5 (1715), DQ51 (1560)| 1       |

MFI – median fluorescence intensity; AR – acute cellular rejection; CAV – coronary artery vasculopathy; NA – not available; DSA – donor-specific antibody.

Table 3. The table shows the presence of donor-specific antibodies against heart donor and homograft donor in each individual patient. The number of biopsy proven acute cellular rejections and coronary artery angiography findings classified according to the ISHLT guidelines are also presented.
antibodies in the development of CAV and significant graft dysfunction in 1 of the latter patients (Patient 4), however, the prevalence of biopsy proven rejections and CAV did not differ from historical controls. To the best of our knowledge, no previous study reporting the homograft donor DSAs after HTx has been published.

According to the previous studies, it is likely that exposure to the vascular allograft leads to humoral response and HLA immunization [15–17]. Meyers et al. have shown that the use of cryopreserved allograft tissue in the Norwood procedure is associated with a significant humoral response in the majority of patients, especially in those who were mismatched for HLA type [15]. The major concern with HLA antibodies is consequently prolonged waiting times for HTx, increased risk for antibody-mediated rejection due to pre-existing HLA antibodies, and dysfunction of the vascular allograft [21]. The data about the effect of homograft induced HLA sensitization on rejection rate and graft function after HTx are scarce. In pediatric heart transplant recipients, a PRA 10% or more was associated with increased mortality and rejection rate compared with those with a PRA under 10% [5]. Our retrospective analysis on biopsy-proven acute rejection and CAV rate did not reveal any statistically significant difference between the HTx recipients with vascular allograft and our transplant population in general. Our data do not support the initiation of immunosuppression for recipients of a vascular allograft from deceased donors.

The immunogenicity of the allograft depends on treatment and preservation of the graft. Vascular allograft treatment model that removes cellular elements leaving only the tissue matrix has been developed. These decellularization techniques have been shown to reduce the risk for homograft-induced sensitization compared to DMSO-treated grafts [22]. Cryopreserved grafts contain viable endothelial cells, which increases the risk for an immunogenic response [23,24]. Despite this recent development in the homograft treatment methods, there are hundreds of patients with grafts that were inserted in the 1990s when less effective decellularization methods were commonly used. In our cohort, 1 patient developed de novo DSA against the homograft donor more than 10 years after the operation, which should be taken into consideration when preparing patients for heart transplantation.

The major caveats of the study were the small sample size and retrospective nature. However, there were also strengths, such as systematic routine follow-up of HLA antibodies, EMBs, and coronary angiographies. Data regarding the HLA genotype of the homograft and heart donors were also available from nearly all participants.

Conclusions

We conclude that the risk for development of HLA antibodies prior to HTx is relatively small among patients with vascular allograft from deceased donor. Donor-specific HLA antibodies against homograft donor might appear after HTx. However, the clinical importance of this finding remains to be studied.

Conflicts of interest

None.

References:

1. Smith JD, Banner NR, Hanour IM et al: De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant, 2011; 11: 312–19
2. Ho EK, Vlad G, Vasilescu ER et al: Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Hum Immunol, 2011; 72: 5–10
3. Tran A, Fixler D, Huang R et al: Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation. J Heart Lung Transplant, 2016; 35: 87–91
4. Chen CK, Manlhiot C, Conway J et al: Development and impact of de novo anti-HLA antibodies in pediatric heart transplant recipients. Am J Transplant, 2015; 15: 2215–22
5. Jacobs JP, Quintessenza JA, Boucek RJ et al: Pediatric cardiac transplantation in children with high panel reactivity antibody. Ann Thorac Surg, 2004; 78: 1703–9
6. Godown J, Slaughter JC, Fossey SC et al: Risk factors for development of donor-specific antibodies after pediatric heart transplantation. Pediatr Transplant, 2015; 19: 906–10
7. Kirk R, Edwards LB, Kucheryavaya AY et al: The registry of the International Society for Heart and Lung Transplantation: Fourteenth pediatric heart transplantation report – 2011. J Heart Lung Transplant, 2011; 30: 1095–103
8. Schumacher KR, Almond C, Singh TP et al., on behalf of the PHTS Study Group Investigators: Predicting graft loss by 1 year in pediatric heart transplantation candidates. An analysis of the pediatric heart transplant study database. Circulation, 2015; 131: 890–98
9. Bechtel JF, Bartels C, Schmidtko C et al: Does histocompatibility affect homograft valve function after the Ross procedure? Circulation, 2001; 104: 125–28
10. Pompilio G, Polvani G, Piccolo G et al: Six-year monitoring of the donor-specific immune response to cryopreserved aortic allograft valves: Implications with valve dysfunction. Ann Thorac Surg, 2004; 8: 557–63
11. Yap CH, Skillington PD, Matalanis G et al: Anti-HLA antibodies after cryopreserved allograft valve implantation does not predict valve dysfunction at three-year follow up. J Heart Valve Dis, 2006; 15: 540–44
12. Yap CH, Skillington PD, Matalanis G et al: Human leukocyte antigen mismatch and other factors affecting cryopreserved allograft valve function. Heart Surg Forum, 2008; 11: E42–45
13. Benedetto B, Lipkowitz G, Madden R et al: Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization. J Vasc Surg, 2001; 34: 139–42
14. Boulland LML, Naper C, Skauby MH: Presensitization revisited: Pitfalls of vascular allografts in transplant candidates. Clin Kidney J, 2014; 7: 65–67
15. Hooper DK, Hawkins JA, Fuller TC et al: Pancreatic antibodies late after allograft implantation in children. Ann Thorac Surg, 2005; 79: 641–45
16. Meyer SR, Campbell PM, Rutledge JM et al: Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation. Eur J Cardiothorac Surg, 2005; 27: 554–60

17. O’Connor MJ, Lind C, Tang X et al: Persistence of anti-human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood. J Heart Lung Transplant, 2013; 32: 390–97

18. Stewart S, Winters GL, Fishbein MC et al: Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant, 2005; 24: 1710–20

19. Mehra MR, Crespo-Leiro MG, Dipchand A et al: International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy – 2010. J Heart Lung Transplant, 2010; 9: 717–27

20. Raissadati A, Pihkala J, Jahnukainen T et al: Late outcome after paediatric heart transplantation in Finland. Interact Cardiovasc Thorac Surg, 2016; 23: 18–25

21. Rajani B, Mee RB, Ratliff NB: Evidence for rejection of homograft cardiac valves in infants. J Thorac Cardiovasc Surg, 1998; 115: 111–17

22. Shaddy RE, Fuller TC, Anderson JB et al: Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg, 2004; 77: 1734–39

23. Madden R, Lipkowitz G, Benedetto B et al: Decellularized vein allografts used for hemodialysis access do not cause allosensitization or preclude kidney transplantation. Am J Kidney Dis, 2002; 40: 1240–43

24. Lindford AJ, Lauronen J, Juvonen E et al: Evaluation of human leukocyte antigen sensitization in burn patients after treatment with skin allografts and transfusion of blood products. Transplant Int, 2017; 30: 320–22